<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02573116</url>
  </required_header>
  <id_info>
    <org_study_id>2013/44</org_study_id>
    <nct_id>NCT02573116</nct_id>
  </id_info>
  <brief_title>Impact of Treatment of Periodontis on Endothelial Function in Patients With Obstructive Sleep Apnea</brief_title>
  <acronym>EndothSAS</acronym>
  <official_title>Impact of Treatment of Periodontis on Endothelial Function in Patients With Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Foch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the add-on effect on endothelial dysfunction of treatment of periodontitis in
      patients with chronic periodontitis and severe obstructive sleep apnea treated by CPAP.
      Patients with and without chronic periodontitis will be treated by CPAP for 20 weeks. At V2
      (10 weeks), endothelial dysfunction will be assessed by the Reactive Hyperemia- Peripheral
      Artery Tone index. The endothelial dysfunction of the patients will be also assessed at V3
      (20 weeks) after periodontitis treatment for the group of patients with chronic
      periodontitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At V2, patients with periodontitis will have full-mouth intensive removal of denatl plaque
      biofilms with the use of scaling and root planing. The add-on effect of the periodontitis
      treatment on endothelial dysfunction will be assessed ten weeks later (V3) in comparison with
      V2 by taking into account with the effect of 10 weeks of CPAP in the control group with
      severe OSA but not periodontitis.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient recruitment
  </why_stopped>
  <start_date type="Actual">March 24, 2014</start_date>
  <completion_date type="Actual">June 6, 2017</completion_date>
  <primary_completion_date type="Actual">December 22, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>20 weeks</time_frame>
    <description>measure of Reactive Hyperemia- Peripheral Artery Tone index with Endopat</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>10 weeks</time_frame>
    <description>measure of Reactive Hyperemia- Peripheral Artery Tone index with Endopat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood biomarkers</measure>
    <time_frame>0, 10 and 20 weeks</time_frame>
    <description>hsCRP, leptin, adiponectin, E-selectin and orosomucoid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale</measure>
    <time_frame>0, 10 and 20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Cardiovascular Disease in Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Obstructive sleep apnea with chronic parodontis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with severe obstructive sleep apnea (OSA) and chronic parodontis treated for OSA by continuous positive airway pressure (CPAP) and intensive periodontal treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obstructive sleep apnea without chronic parodontis</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients with severe OSA treated by CPAP</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>scaling and root planing</intervention_name>
    <description>full-mouth intensive removal of subgingival dental plaque biofilms with the use of scaling and root planing after the administration of local anesthesia</description>
    <arm_group_label>Obstructive sleep apnea with chronic parodontis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  severe OSA defined by an apnea hypopnea index &gt; or = 30 per hour

          -  with or without chronic parodontitis

        Exclusion Criteria:

          -  non equilibrated diabetes

          -  obesity (BMI &gt; or = 40)

          -  active smoker (&gt; 1 pack per day (20 cigarettes))

          -  pregnancy

          -  antibiotics within the preceding three months

          -  prophylactic antibiotherapy required for the parodontitis treatment

          -  acute parodontitis or all parontal pathology requiring immediate therapy

          -  less than 10 teeth
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Priscilla Henno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP, Hôpital Européen Georges Pompidou</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 8, 2015</study_first_submitted>
  <study_first_submitted_qc>October 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2015</study_first_posted>
  <last_update_submitted>October 1, 2018</last_update_submitted>
  <last_update_submitted_qc>October 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obstructive sleep apnea</keyword>
  <keyword>endothelial dysfunction</keyword>
  <keyword>periodontitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

